Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR

Occup Med (Lond). 2015 Apr;65(3):256-8. doi: 10.1093/occmed/kqu193. Epub 2015 Feb 5.

Abstract

We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

Keywords: Asthma hazard index; respiratory sensitizer; tafenoquine..

MeSH terms

  • Adult
  • Aminoquinolines / adverse effects*
  • Aminoquinolines / therapeutic use
  • Antimalarials / adverse effects*
  • Antimalarials / therapeutic use
  • Asthma, Occupational / diagnosis*
  • Asthma, Occupational / etiology*
  • Drug Industry*
  • Humans
  • Male
  • Quantitative Structure-Activity Relationship*
  • Rhinitis / etiology

Substances

  • Aminoquinolines
  • Antimalarials
  • tafenoquine